Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
about
Bone Tumor Environment as a Potential Therapeutic Target in Ewing SarcomaDevelopment of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imagingStrategies for the targeted delivery of therapeutics for osteosarcoma.Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destructionClusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcomaInduction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcomaEffect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.Monitoring tumor metastases and osteolytic lesions with bioluminescence and micro CT imagingHypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patientsFeasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupDownregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine OsteosarcomaIntra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration.Past, present and future of therapies in pediatric sarcomas.Emerging drugs for high-grade osteosarcoma.Animal models of osteosarcoma.Pharmacokinetic evaluation of zoledronic acid.Current therapeutic strategies and novel approaches in osteosarcoma.Physiological, Tumor, and Metastatic Niches: Opportunities and Challenges for Targeting the Tumor Microenvironment.Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy.Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.Metastatic osteosarcoma: a challenging multidisciplinary treatment.Zoledronic acid induces apoptosis and autophagy in cervical cancer cells.Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.Implications of high-dosage bisphosphonate treatment on bone tissue in the jaw and knee joint.Bisphosphonate conjugation for bone specific drug targeting.
P2860
Q26771376-C9D554E7-C985-467A-A5ED-2E74FC487F98Q28538391-9BBEAB65-EBFA-44B7-ACD4-DC1D786087CAQ34179495-A5F794CD-3D20-49C5-B618-29C44ABBF98DQ34284100-A64B043C-7B5B-4436-9FED-4806DC0196BEQ34365891-59C7EAD6-103E-4B69-805A-17345DD22C9DQ34786566-DD827222-68C3-4F55-94B6-8EC260E2762EQ34829069-29AEC01A-E21B-4493-B98C-87332AB36937Q35203096-A7F11EB5-DE0A-450D-A629-DF091B04D773Q36072569-C98D193F-2BE6-4B79-A8DA-64DDE27C95D1Q36337775-743B5BF3-3A38-4A8F-BA1E-151B4AC623FBQ36846801-309DB4D2-FFDE-4AC5-859C-D315D5590CF0Q36946864-0B24785F-CD4A-4D82-BF03-BB08868C2FD3Q37384979-92732C50-1D1D-48E6-9F14-FFEDD94257B3Q37603941-1554A285-07D9-41A8-8319-7BBFD7D33DF0Q37725915-AF60692A-2999-425C-A399-9811F3D305B0Q37778400-C85B5CE9-A2BB-47C3-8672-304C30609ADEQ37782099-4FF9F7C1-C500-410E-BC7E-D2FBFE6D3D23Q37874629-308FA005-DFDB-498D-9F73-50067478CF03Q38161735-918C6F5C-9ED6-4FEB-A316-AA7A0376E340Q38582873-4FD1F77A-73FB-4BFF-8927-5439B0D50FEBQ38727632-DA4A14C1-9619-4BDB-B6E3-E082BFAF4D04Q38730126-46D0C455-CE7F-4E32-8493-1963CD2A23AEQ38783252-CE14382E-449A-4874-89E3-793AF9F098D7Q38964271-A68E783F-B5F1-41E6-893A-CF30F524F45BQ39453295-6F2C49EF-3521-4629-91A5-01BD98A7D529Q39659194-7D5F0043-91CE-4E88-976F-D7363040661FQ46433634-F5200F2B-4C43-4BA2-8EAC-7A1E1F476525Q55515922-15407022-56F1-4255-846C-10D8DA59577D
P2860
Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Zoledronic acid inhibits both ...... coma lesions in a mouse model.
@en
type
label
Zoledronic acid inhibits both ...... coma lesions in a mouse model.
@en
prefLabel
Zoledronic acid inhibits both ...... coma lesions in a mouse model.
@en
P2093
P2860
P1476
Zoledronic acid inhibits both ...... coma lesions in a mouse model.
@en
P2093
Agatha Labrinidis
Andreas Evdokiou
David M Findlay
Shelley Hay
Vasilios Liapis
P2860
P304
P356
10.1158/1078-0432.CCR-08-1616
P407
P577
2009-04-28T00:00:00Z